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Abstract
Progesterone receptor status is a marker for hormone responsive-
ness and disease prognosis in breast cancer. Progesterone
receptor negative tumours have generally been shown to have a
poorer prognosis than progesterone receptor positive tumours.
The observed loss of progesterone receptor could be through a
range of mechanisms, including the generation of alternatively
spliced progesterone receptor variants that are not detectable by
current screening methods. Many progesterone receptor mRNA
variants have been described with deletions of various whole,
multiple or partial exons that encode differing protein functional
domains. These variants may alter the progestin responsiveness of
a tissue and contribute to the abnormal growth associated with
breast cancer. Absence of specific functional domains from these
spliced variants may also make them undetectable or
indistinguishable from full length progesterone receptor by
conventional antibodies. A comprehensive investigation into the
expression profile and activity of progesterone receptor spliced
variants in breast cancer is required to advance our understanding
of tumour hormone receptor status. This, in turn, may aid the
development of new biomarkers of disease prognosis and improve
adjuvant treatment decisions.
Introduction
Breast cancer is the most commonly diagnosed cancer in the
UK, with 44,659 new cases diagnosed in 2004 [1]. Survival
among women diagnosed with the disease is relatively good;
however, 12,509 breast cancer related deaths in 2005 [1]
demonstrate the potential for improving both diagnostic and
therapeutic procedures.
After menarche, the cyclical release of the steroid hormones
oestrogen and progesterone stimulates the primitive ducts of
the immature breast to differentiate into terminal end buds,
which branch into alveolar buds. During pregnancy, high
circulating steroid hormone levels stimulate increased lobular
differentiation to the mature secretory gland. Upon withdrawal
of sex steroid hormones at menopause, involution to an
undifferentiated morphology occurs [2].
Normal mammary ducts consist of a layer of luminal epithelial
cells, surrounded by a layer of myoepithelial cells, encased in
delimiting fibroblasts set in a fatty, collagenous stroma [3].
Most breast carcinomas are of epithelial origin and are either
localised to the duct/lobule of origin or capable of invading
surrounding stroma [4]. Whilst age is the biggest contributory
risk factor for developing breast cancer, use of hormone
replacement therapy (HRT) and oral contraceptives have also
been implicated, implicating hormone signalling in breast
cancer development [1,4]. A further increased risk with com-
bined oestrogen-progesterone HRT compared to oestrogen
alone also bears out the significant role of progesterone
signalling through progesterone receptor (PR) in breast
cancer development [5-7].
PR, along with oestrogen receptor (ER), status is routinely
measured in breast cancer specimens. PR+ patients are
more likely to respond to hormonal therapies and survive
disease [8]. Approximately 40% of breast tumours are
ER+/PR+ and these patients are considered to have the best
prognosis and are most likely to respond to hormonal
therapies [4,9]. These cancers are associated with a lower
rate of cell proliferation and well differentiated tumours,
leading to a better prospect of overall survival [9]. Since PR is
an oestrogen responsive gene, PR positivity indicates not
only ER being present but also functional [8]. However, a
small proportion of tumours are ER-/PR+ and still respond
more favourably to hormonal therapies than ER-/PR- tumours
[9,10], demonstrating the independent importance of PR in
breast cancer development and treatment, not just as an
indicator of ER function.
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Potential mechanisms for PR loss or down-regulation in
response to growth factor signalling have been described. In
some tumours PR- status appears to correlate with
upregulation of epidermal growth factor receptor; it has been
proposed that cross-talk between ER and epidermal growth
factor receptor pathways may account for the resistance to
selective oestrogen receptor modulators (SERMS; for
example, Tamoxifen) of PR- tumours, which can still respond
to removal of oestrogen signal by aromatase inhibitors
[10,11]. Another study has shown that insulin-like growth
factor-1 inhibits transcription of PR in breast cancer cells, via
the PI3K/Akt/mTOR signalling pathway, which appears to be
independent of ER levels or activity [12]. Loss of PR also
occurs by a phosphorylation-dependent process in which
ligand binding activates PR phosphorylation by mitogen-
activated protein kinases, which in turn targets the receptors
to the ubiquitin-proteosome for degradation [13]; these
researchers demonstrate that growth factors can
paradoxically activate transcription of PR yet rapidly down-
regulate PR protein. It is plausible, therefore, that PR variants
may be difficult to detect at the protein level because they
have relatively short half-lives and rapid turnover.
In addition to down-regulation of PR by growth factor-
oestrogen receptor cross-talk, other potential mechanisms for
the development of PR- tumours include: low circulating
oestrogen levels in post menopausal women being insufficient
to generate detectable levels of PR, consistent with the higher
incidence of ER+/PR- tumours in older women; loss of
heterozygosity at the PR gene; or hypermethylation of the PR
promoters, common in many cancer cell types, including
breast cancer, causing transcriptional silencing [11,14,15].
One further possibility is that alternative splicing of PR pre-
mRNA might generate cancer specific PR variants that are not
detectable by current pathological screening methods, thus
leading to potential misdiagnosis of a tumour as PR-.
This review will describe the structure and function of PR,
and outline the mechanisms of alternative splicing, their
implications in cancer and evidence for the existence of
alternatively spliced PR isoforms. The potential gain or loss of
function associated with each PR variant and their
significance in breast cancer will be discussed.
Progesterone receptor structure and function
The human PR gene consists of eight coding exons separa-
ted by seven non-coding introns [16]. The two main nuclear
isoforms, PR-A and PR-B [17-20], are independently
regulated from defined promoter regions within the PR gene
[18,21]. PR-A is a truncated form of PR-B, lacking the amino-
terminal 164 amino acids that form the third transactivation
domain (AF-3) [18,20]. Other than this, the two forms are
structurally identical (Figure 1).
PR is a member of the steroid/thyroid hormone-retinoid
receptor superfamily of ligand activated nuclear transcription
factors [18,22]. The mechanisms by which PR regulates
hormone-response genes are complex. Progesterone binds
PR, inducing a conformational change in PR causing its
nuclear translocation, dimerisation and interaction with
specific DNA progesterone response elements (PREs)
present in the promoter regions of target genes. However,
the presence of a PRE does not necessarily predict progestin
responsiveness. PR can also mediate its effect independently
of PREs, through the protein-protein interactions of PR with
other sequence-specific transcription factors [23]. Protein
products from PR target genes are involved in a diverse
range of cellular activities, including transcription, steroid and
lipid metabolism, cell growth and apoptosis, protein and
nucleic acid processing and membrane associated signalling,
indicating a broad range of potential progesterone effects
[24]. Some of these proteins are associated with mammary
gland and breast cancer development, including the
transcription factors STAT5A and C/EBPβ.
In breast cancer cells expressing either PR-B or PR-A, most
PR regulated genes are reported to be controlled by PR-B
[24], less by PR-A and only a minority by both isoforms. PR-A
has been shown to act as a trans-dominant repressor of PR-
B controlled transcription in a cell and promoter specific
manner [24,25]. The balance of PR isoform expression is also
important in breast cancer management. Overexpression of
PR-A protein compared to PR-B is common in breast cancer
[17,26], changing progestin responsiveness of cells [26].
Predominant PR-A protein expression signifies a poorer
outcome of hormonal therapies [27], and predominance of
PR-B poorer outcome of chemotherapy. Predominance of
one isoform is also seen in women at high risk of breast
cancer, for example, women with a BRCA1 or BRCA2
mutation commonly exhibit a lack of PR-B [26]. Therefore, not
only could PR variants lead to incorrect assessment of
hormone receptor status, but could also alter the progestin
responsiveness of tissue, providing potential new indicators
of efficacy and targets for therapeutics.
In addition to the nuclear hormone receptors PR-A and PR-B,
a truncated and predominantly cytoplasmic PR protein has
also been described. PR-C is a 60 kDa protein, first detected
in the T47-D breast cancer cell line, resulting from initiation at
a methionine at position 595 [28] and is capable of forming
heterodimers and modulating the activity of PR-A and PR-B in
vitro [28,29]. The PR-C protein lacks a full DNA binding
domain (DBD) [30] as well as the first two transactivation
domains (AF-3 and AF-1), so although potentially able to bind
hormone, it would not directly bind PRE (Figure 1c).
However, PR-C may still influence transcription events since
it has the capacity to dimerise and also interact with common
nuclear co-factors. A potential physiological role for PR-C in
human pregnancy has been proposed [31]; this study shows
that PR-C mRNA and protein levels significantly increase
within the fundus of uterus of women in labour. The authors
suggest that the observed increase in the ratio of PR-C to
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PR-B may influence functional progesterone withdrawal by
blocking the activity of PR-B to maintain uterine quiescence
in pregnancy [31].
Alternative splicing
Alternative pre-mRNA splicing is a vital mechanism for
generating protein diversity from a relatively small number of
genes. In excess of 60% of all human genes undergo
alternative splicing. Splicing occurs at sites determined by
the presence of a 5’ donor splice sequence (usually ending -
GU), a branch point adenosine and a 3’ acceptor splice
sequence (usually ending -AG) within pre-mRNA sequences
[32,33]. The proximity of cis-regulatory sequences, either
enhancers or silencers of exon or intron splicing, influences
the binding of different trans-splicing factors to the splice
sites (Figure 2a) and aids assembly of the spliceosome multi-
protein complex, resulting in cleavage and ligation of introns
and exons, respectively [32,33]. At least five basic types of
alternative splicing have been described [32-34] (Figure 2b).
A wide range of alternatively spliced genes have been
described in cancers [33,35], affecting disease initiation,
resistance to apoptosis, invasion and angiogenesis [36].
Alternative splicing appears to be increased in cancer,
possibly due to mutations in trans-splicing or cis-regulatory
elements allowing increased competition from cryptic splice
sites and misdirected spliceosome formation [34]. Alterna-
tively spliced genes involved in breast cancer have been
observed; BRCA1 variants [35,37] as well as variants of
other members of the steroid receptor superfamily such as an
androgen receptor variant lacking exon 3 and several ER
variants with differing expression in normal and tumourigenic
breast tissues [38-40].
Alternatively spliced progesterone receptor
isoforms
As well as PR-A, PR-B and PR-C, several other smaller
isoforms encoded by the PR gene have also been described
[28,41-44] (Figure 3). Screening of a testicular cDNA library
revealed a PR mRNA isoform containing a novel sequence
before exon 4 termed exon S [41]; mRNA for this isoform
was found to be present in ejaculated spermatozoon and the
uterine endometrium. A protein encoded from this mRNA
would lack the entire DBD but would most likely possess
nearly the entire sequence for the progesterone-binding
domain and be capable of dimerisation. This isoform, PR-S,
and another isoform, PR-T, resulting from retention of another
intronic sequence before exon 4 (exon T) [42], could give rise
to identical proteins. Neither exon S nor exon T encode a
translation initiation site, so translation is likely to start at the
first methionine in exons 4 to 8 [42]. Exons S and T are
located between exons 3 and 4 in the PR gene [45]. Since
both PR-S and PR-T proteins lack the ability to bind DNA,
they may be important in mediating non-genomic PR
mediated responses or recruiting co-factors to PR hetero-
dimers.
A study of endometrial carcinomas revealed a variant PR
mRNA that contained a 252 base-pair insertion between
exons 4 and 5 [44]. This was termed PR-i45 and the insertion
is the result of transcription of two intronic sequences termed
exons i45a and i45b. The protein translated from PR-i45
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Figure 1
Progesterone receptor (PR) gene and main isoforms. (a) Exon organisation map of the PR gene, showing PR-A and PR-B promoters (indicated by
arrows). (b) PR-B and PR-A protein structures. The A/B region is encoded by exon 1 and part of exon 2, and contains the PR-B specific
transactivation domain AF-3, AF-1, common to PR-B and PR-A, and the PR-A specific inhibitory domain (ID). The C region forms the DNA binding
domain (DBD); each of exons 2 and 3 encodes one zinc finger. The D region is encoded by exon 4 and part of exon 3, and forms the hinge region
responsible for the nuclear location signal (NLS). The E region contains AF-2, common to PR-B and PR-A, and the hormone (ligand) binding
domain (LBD), encoded by exons 4 to 8. (c) PR-C, an amino-terminally deleted PR protein predicted to result from alternative translation initiation
at a methionine at position 595. PR-C lacks a complete DBD and the first two transactivation domains (AF-3 and AF-1).
mRNA would have the normal amino-terminal domain of
genomic PR, the DBD and nuclear location signal (NLS). A
change in reading frame due to the insertion would cause
truncation of the ligand binding domain (LBD) [44].
PR-M mRNA was discovered in the T47D breast cancer cell
line that contained a 5’-untranslated region consistent with
use of a promoter within intron 3 [43]. This encoded a short
5’ signal sequence of hydrophobic amino acids, suggesting
that the protein may be processed for either expression on
the cell membrane or secretion. PR-M contains the full LBD
and dimerisation domain (DD) so is likely to be physio-
logically active despite lacking the DBD [43], consistent with
a role on the plasma membrane or as a secreted protein. PR-
M was later detected in the PR- T47D-Y cell line by immuno-
fluorescent antibody staining. Cells that overexpressed PR-
M demonstrated a decreased rate of calcium influx consis-
tent with PR-M functioning as a membrane bound protein
associated with non-genomic responses to progesterone
[46].
Other progesterone receptor spliced variants
The initial observation of a 78 kDa protein detected by anti-
PR antibodies [17,47] prompted the analysis of alternatively
spliced variant (ASV) PR mRNAs by reverse transcription
PCR. Due to the predicted size of proteins encoded by PR
variant mRNAs, a deletion of exon 3 or part of exon 4 was
suggested [47]. If this was a PR protein lacking either of
these exons, it could still be transcriptionally active as it was
capable of binding progesterone [47] and, therefore, may be
able to elicit a response or modulate the activity of other PR
isoforms.
Many alternatively spliced, whole exon deleted, PR variant
mRNAs have since been described. Exon 2 deleted PRΔ2
was found in breast tumour tissue and in two PR+ breast
cancer cell lines MCF-7 and T47DCO [47,48]. A protein
encoded from this mRNA would lack the first zinc finger of the
DBD, making DNA binding doubtful, and a change in reading
frame would lead to the insertion of a stop codon in exon 3 so
it would also lack a LBD [48]. It is probable, therefore, that
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Figure 2
Regulation and different patterns of alternative splicing. (a) Alternative pre-mRNA splicing involves a complex interplay of trans-acting splicing
factors with numerous cis-acting regulatory elements within the precursor mRNA sequences of eukaryotic genes. Trans-acting factors recognise
and interact with different cis-acting RNA motifs present within the pre-mRNA sequence of genes; these include 5’ donor and 3’ acceptor sites at
exon-intron boundaries; exon and intron enhancer elements (ESE, ISE), which can promote the use of specific splice sites; and exon and intron
silencer elements (ESS, ISS), which when bound by proteins can repress the use of specific splice sites (adapted from [59]). (b) Different patterns
of alternative splicing include: (i) normal pattern of splicing - removing introns 1, 2 and 3; (ii) whole exon exclusion - introns 1, 2 and 3, and entire
exon 2 are removed; (iii) mutually exclusive exons - either exon 2 or exon 3 is removed and both exons are never retained together; (iv) intron
retention - intron 2 is retained in the mRNA; and (v) cryptic splice sites - exon 2 contains a 3’ cryptic splice site and exon 3 contains a 5’ cryptic
splice site. These compete with the native splice site to generate mRNA lacking part of an exon.
were this protein translated it would be unable to bind DNA or
hormone so not be functional as a PR. Exon 3 deleted PRΔ3
mRNA was seen at low levels in most breast tumour samples
examined and in T47D cells [47,49]. A protein from this ASV
would lack the second zinc finger of the DBD but might still be
active if it were able to bind progesterone and dimerise with
other PR forms. Exon 4 deleted PRΔ4 mRNA was detected in
both normal and tumour tissue from the breast and in T47-D
cells [47,48,50]. This variant was also found in normal
endometrial, normal ovarian and ovarian endometriotic tissues
[51] as well as in vascular smooth muscle [52]. The putative
protein from this mRNA would lack the hinge region, so be
segregated from the nucleus and would lack the proximal end
of the LBD, though the rest of the LBD would be intact. It has
been demonstrated that PRΔ4 is unable to bind PRE and is
not responsive to the progestin R5020 [48]. It is unlikely,
therefore, to function as a PR, but may compete for dimerisa-
tion with other PR rendering them inactive, or compete for co-
factor binding.
Exon 6 deleted PRΔ6 mRNA has been detected in normal
and tumour samples from the breast [50] and has since been
detected more frequently in tumour than normal breast tissue,
and at a higher rate in PR- tumours than PR+ [53]. PRΔ6
mRNA has also been detected in tissue samples from
vascular smooth muscle [52], normal ovaries, ovarian endo-
metriosis and normal endometrium [51]. The protein encoded
from PRΔ6 mRNA lacks a functional LBD but possesses the
NLS, ability to dimerise and bind DNA and has been shown
to be a dominant negative inhibitor of wild-type PR-A and PR-
B function [48]. Therefore, PRΔ6 protein expression, which
may be elevated in breast cancer, could be an important
regulator of PR function in the disease. It has further been
demonstrated that PRΔ6 is able to bind PRE independent of
progestin activation and suggested that this constitutive
binding of transcriptionally inactive PRΔ6 to PRE may block
wild-type PR binding [48]. The protein encoded by PR-i45
mRNA is likely to be similar in structure to a PRΔ6 protein, so
may have a similar ability to inhibit PR-A and PR-B [45].
Interestingly, the expression of PRΔ6 and PRΔ4, relative to
wild-type PR, in vascular smooth muscle appears to be
decreased in post-menopausal women [52]. If this pattern
was also true in breast tissue, then perhaps the associated
change in progesterone responsiveness could relate to the
increased risk of developing breast cancer after menopause.
However, in this very small study, three of the four post-
menopausal subjects were receiving oestrogen only HRT
[52]. Since PR is, in part, an oestrogen responsive gene, the
use of exogenous oestrogens could alter PR expression.
Perhaps the increased risk of breast cancer associated with
HRT could reflect a change in PR variant expression.
As well as these single exon deleted mRNAs, many variants
exist in which multiple exons have been deleted; PRΔ2+3
[47,49], PRΔ3+4 [54], PRΔ3+6 [50], PRΔ4+6 [51],
PRΔ5+6 [50], PRΔ4+5+6 [51], PRΔ3+4+5+6 [54]. Some
of these would be unlikely to encode functional PR since they
would lack too many of the protein domains; for example,
PRΔ4+6 would lack the nuclear location signal and LBD but
has been shown to be present more frequently in malignant
than ‘normal’ breast tissue [55], and is perhaps indicative of a
breakdown in normal splicing control mechanisms. Further-
more, any transcriptionally inactive PR variants expressed
may be able to compete with wild-type receptors for co-factor
binding (‘squelching’), thereby interfering with normal
progestin responsiveness. In this context, PR mutants deleted
of their LBD have been shown to be constitutively active and
capable of binding PRE [56]. In addition, ASV such as
PRΔ5+6, would encode a protein with a complete DBD and
NLS as well as being able to dimerise and possessing both
AF-1 and AF-2. This protein has been demonstrated to be a
dominant repressor of wild-type PR function, but is not itself
progestin responsive or able to bind PRE [48], and its distri-
bution in a wide range of normal and pathological tissue
types [48,50,51] suggests an important physiological role.
Another ASV with the potential to encode a functional protein
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Figure 3
Truncated progesterone receptor (PR) isoforms. The upper part of
each diagram shows the PR gene; darker shading indicates regions
removed by splicing, lighter regions those retained in mRNA. The lower
part of each diagram shows the predicted protein structure. PR-S:
retention of intronic sequence termed exon S and initiation of
transcription within exons 4 to 8. PR-T: retention of intronic sequence
termed exon T and initiation of transcription within exons 4 to 8. PR-S
and PR-T mRNA are likely to give rise to identical proteins that are
amino-terminally truncated, lacking AF-1, AF-2 and the DNA binding
domain. PR-i45: retention of two intronic sequences termed exons
i45a and i45b leads to a change in reading frame and truncation of the
protein E region so the PR-i45 protein lacks a functional ligand-binding
domain and dimerisation domain. PR-M: inclusion of an intronic 5’
untranslated region sequence causes amino-terminal truncation and
leads to encoding of a protein with a 5’ signal sequence and complete
ligand-binding domain and dimerisation domain, consistent with a
function as a membrane bound receptor.
is PRΔ2+3. This putative variant protein would lack the entire
DBD but could still modulate PR activity by binding
progesterone, dimerising and migrating to the nucleus. Some
of the variants, although unlikely to encode functional PR,
seem to be tissue specific. PRΔ3+6 has to date only been
seen in breast tumour tissue, and PRΔ4+5+6 only in endo-
metrial tissue, suggesting that any protein encoded from
these mRNA could have an important role in a specific
progesterone target tissue. Alternatively, the presence of the
mRNA could be indicative of a breakdown in splicing control
mechanisms in cancer.
Other ASV mRNAs are seen that lack a specific part of an
exon rather than being whole exon deleted. PRΔ4/2 mRNA, in
which the first 126 base-pairs of exon 4 have been deleted,
was detected frequently but at a low level in breast tumour
tissue [47,49]. This deletion could be due to a donor splice
sequence in intron 3 and an acceptor splice sequence within
exon 4 forming a cryptic splice site and acting in competition
to the normal exon 4 splice site in some transcripts [49].
PRΔ4/2 has since been observed in normal endometrial
tissue [57] and would encode a protein lacking the NLS but
probably able to dimerise and bind progesterone so could
well be able to modulate PR function. A second partial exon
deleted PR variant mRNA is PRΔ6/2 [58] in which a 52 base-
pair section of exon 6 has been deleted. This mRNA has
been detected at a far greater frequency in tumour compared
to normal breast tissue, suggesting that the protein could be
functional in cancer and may be a result of a cancer
associated breakdown in splicing control. The protein would
lack a fully functional LBD but would retain all of the other
functional domains required to act as a transcription factor.
Two further variants lacking part of exon 6, along with either
exon 3 (PRΔ3+6/2) or exon 4 (PRΔ4+6/2) [58], have been
observed infrequently, but appear specific to breast cancer
tissue. Neither of these variants is likely to encode functional
hormone-responsive receptors but again their presence in
breast cancer tissue suggests mis-splicing leading to a
change in PR expression.
Conclusion
Discrepancies between ER/PR status and response to
hormone therapies could be due to the presence of these
variant PRs (or variant ERs) that are either not detected
(amino-terminally truncated variants) or not distinguishable
from full-length receptor (functional domain deleted variants)
by current screening methods that use antibodies directed
against the PR-A/B common amino-terminal region. It has
already been demonstrated that differences in the ratio of PR-
A:PR-B can affect the outcome of breast cancer treatment
[27]. The discovery of truncated PR isoforms adds another
level of complexity to the study of PR in breast cancer. This is
further complicated by reports of many exon deleted ASV PR
mRNA species in a variety of cell lines, as well as normal and
malignant human tissues. If translated, the proteins encoded
by theses ASV mRNAs may have transcriptional activities that
differ from the full length PR-A or PR-B to which they are
related, or could interact with the full-length PR to modulate
its activity, as is seen with PR-A repression of PR-B [25].
Moreover, PR spliced variants may also modulate PR-A and
PR-B activity indirectly, by competitively binding to common
nuclear co-regulatory proteins.
The expression of any isoform or variant proteins could modify
progesterone responsiveness of a target tissue, for example,
providing a mechanism for the differing responses to the
same dose of progesterone in the uterus (proliferative) and
breast (anti-proliferative) [48]. Variant PR expression breast
cancer could, therefore, provide a mechanism for abnormal
epithelial proliferation. Alternatively, the presence of variant
mRNAs that are not translated to protein could be indicative
of a loss of normal PR expression and thus normal response
to progesterone.
Although the expression of many of these variants is yet to be
reported in breast tissue at the protein level, the possibility
that shorter forms of PR may be functional and perhaps not
detected by conventional screening methods could lead to
discrepancies between the reported PR status of a tumour
and the progression of the disease or response to endocrine
therapies. Therefore, detailed and accurate characterisation
of PR variant expression in breast cancer could generate
novel and more efficient biomarkers of disease prognosis or
targets for therapeutics.
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